Advertisement Pharmaceutical Business review - Page 32 of 5255 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 19, 2025

J&J receives FDA approval for lung cancer therapy

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

The study demonstrated that Rybrevant Faspro has met co-primary pharmacokinetic endpoints. Credit: Johnson & Johnson / PRNewswire.